ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
SK Pharmteco, a contract development and manufacturing organization, plans to invest $260 million in a peptide and small-molecule drug production plant in Sejong, South Korea. The 12,600 m2 facility will be the company’s fifth plant in that country. SK Pharmteco says the plant will be operational in late 2026 and add 300 employees to its workforce. The high global demand for peptides is fueled in part by the popularity of glucagon-like peptide-1 drugs, such as those developed by Novo Nordisk and Eli Lilly and Company.
This article was updated on Oct. 14, 2024, to correct the name of the company in the headline. It is SK Pharmteco, not SK Phamteco.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter